Stevanato Group S.p.A.
No SEC Form 4 filings for $STVN in the last 30 days.
See all $STVN insider activity →Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.
Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.
Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.
Over the past 7 days, alphai's AI scored 3 news stories mentioning STVN (Stevanato Group S.p.A.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent STVN coverage spans financial news, earnings and regulation.
Guidance adjustment plus Alina variable dose pen regulatory approvals and GLP-1/biologics momentum are likely to support higher expectations for 2026-2027 revenue mix.
Q2 results and operational updates (divestiture, margin drivers, order wins, and capacity milestones) provide near-term read-through on execution and demand for differentiated drug delivery.
Guidance update and segment performance (BDS growth, Engineering decline) plus one-time divestiture costs change the earnings outlook and margin trajectory.
European marketing authorizations for liraglutide combination products that incorporate Stevanato’s Alina pen support device platform commercialization and potential incremental device demand.
Stevanato Group's Q1 2026 decline reflects investor concerns over mixed business performance and moderating growth, despite improved margins and high-value solutions. The stock's somewhat-bearish sentiment suggests cautious outlook.
alphai scores every news story that mentions STVN with an AI model for sentiment and relevance, and aggregates insider trades from Stevanato Group S.p.A.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.
6 min readStevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.
7 min readStevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.
6 min readStevanato Group S.p.A. (NYSE: STVN) said liraglutide-based combination products using its Alina variable-dose pen injector received marketing authorizations in multiple European countries. The approvals cover Alina 30 for diabetes and Alina 50 for weight management. Stevanato said the device platform supports scalable manufacturing and integration into existing fill-finish supply chains.
4 min readStevanato Group S.p.A. (NYSE:STVN) experienced a decline in Q1 2026, as noted by Conestoga Capital Advisors in their investor letter. The company's stock struggled due to investors weighing solid results against a mixed underlying business mix and moderating growth profile, with overall revenue growth remaining relatively modest at 5%. Despite improved margins and scaling high-value solutions, the stock was pressured by weakness in the Engineering segment, a transition towards higher-value products, and the decline of oral vs. GLP-1s.
4 min readImage source: The Motley Fool.Thursday, Nov. 6, 2025, at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...
3 min readInvestors interested in Medical - Drugs stocks are likely familiar with Sandoz Group AG Sponsored ADR ( SDZNY Quick QuoteSDZNY - ) and Stevanato Group ( STVN Quick QuoteSTVN - ) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer ...
4 min readInvestors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences ( USNA Quick QuoteUSNA - ) and Stevanato Group ( STVN Quick QuoteSTVN - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
4 min readStevanato (STVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 min readStevanato Group's STVN short percent of float has fallen 3.13% since its last report. The company recently reported that it has 1.96 million shares sold short, which is 4.02% of all regular shares that are available for trading.
2 min read
